Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in RXRX.

← Back to Free Index

RXRX

Analysis as of: 2026-01-20

Recursion Pharmaceuticals, Inc.

Recursion is a clinical-stage TechBio company using automated wet labs plus AI to discover and develop small-molecule medicines and partner programs.

ai biotech healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • Third Party Analyst Consensus

Summary

From platform promise to registrational proof

Upside hinges on turning early AI-derived clinical validation into a registrational pathway and scalable partner economics. Execution is credible but still outcome-gated.

Analysis

Thesis

If REC-4881 becomes a credible registrational program and the Recursion OS converts partner traction into repeatable, multi-program economics, RXRX can re-rate from “cash-runway platform biotech” to a scaled TechBio with meaningful commercial and collaboration revenue by 2031.

Last Economy Alignment

Strong fit to the “compute+robots+data flywheel” (automated labs + owned compute), but upside is still gated by clinical/regulatory proof.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

4.1x (from 5 most recent analyses)

Reasoning

The near-term story is credibility and throughput: REC-4881 is the first clear clinical validation point, while partner milestones and disciplined spend extend runway to keep multiple “shots on goal” alive. By 2031, a mix of one meaningful product and scaled collaboration revenue can justify a mid-single-digit revenue multiple, but execution remains materially clinical-outcome-driven.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The binding constraint is clinical validation: REC-4881 must translate into a registrational plan and at least one meaningful commercial ramp. Secondary risks are financing/dilution (given burn and long timelines), partner milestone lumpiness, and competitive convergence as AI discovery becomes cheaper and more internalized by pharma.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

Investor-conference cadence (J.P. Morgan Healthcare Conference on January 13, 2026; Needham on January 16, 2026) kept focus on 2026 execution plan.
No new clinical dataset released in the last 7–10 days; market focus remains on FDA pathway work for REC-4881 and upcoming internal Phase 1 readouts.
Messaging emphasis appears to be capital discipline + milestone cadence while advancing a smaller set of priority programs.

Upgrade to Builder to also access: Future Considerations

Third Party Analyst Consensus

12-Month Price Target

$7.00

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case